Efficacy of intravenous cidofovir in the treatment of giant molluscum contagiosum in a patient with human immunodeficiency virus

Archives of Dermatology

Volumn 147, Issue 6, 2011, Pages 652-654

  Erickson, Corinne ^a   Driscoll, Marcia ^a   Gaspari, Anthony ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTRIAXONE; CIDOFOVIR; DAPTOMYCIN; FLUOROURACIL;

ADULT; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CD4 LYMPHOCYTE COUNT; DISEASE EXACERBATION; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPROMISED PATIENT; KIDNEY FUNCTION; LABORATORY TEST; MALE; MOLLUSCUM CONTAGIOSUM; NEPHROTOXICITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CYTOSINE; HIV INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MOLLUSCUM CONTAGIOSUM; PHOSPHONIC ACIDS; TREATMENT OUTCOME;

EID: 79953883754     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.20     Document Type: Article

References (15)

1. Pereira B, Fernandes C, Nachiambo E, Catarino MC, Rodrigues A, Cardoso J. Exuberant molluscum contagiosum as a manifestation of the immune reconstitution inflammatory syndrome. Dermatol Online J. 2007;13(2):6.
2. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis. 2009;48(1):101-107.
3. Cronin TA Jr, Resnik BI, Elgart G, Kerdel FA. Recalcitrant giant molluscum contagiosum in a patient with AIDS. J Am Acad Dermatol. 1996;35(2, pt 1):266-267.
4. Briand S, Milpied B, Navas D, Thomare P, Stalder JF. 1% topical cidofovir used as last alternative to treat viral infections. J Eur Acad Dermatol Venereol. 2008; 22(2):249-250.
5. Davies EG, Thrasher A, Lacey K, Harper J. Topical cidofovir for severe molluscum contagiosum. Lancet. 1999;353(9169):2042. (Pubitemid 29271758)
6. Meadows KP, Tyring SK, Pavia AT, Rallis TM. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol. 1997;133(8):987-990. (Pubitemid 27351873)
7. Toro JR, Wood LV, Patel NK, Turner ML. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol. 2000;136(8):983-985. (Pubitemid 30629125)
8. Zabawski EJ Jr. A review of topical and intralesional cidofovir. Dermatol Online J. 2000;6(1):3.
9. Zabawski EJ Jr, Cockerell CJ. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol. 1998;39(5, pt 1):741-745. (Pubitemid 28519026)
10. Ibarra V, Blanco JR, Oteo JA, Rosel L. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Derm Venereol. 2000;80(4):315-316.
11. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Intern Med. 1997;126(4):257-263.
12. Centers for Disease Control and Prevention (CDC). Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(19):532-536.
13. Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003;59(3):163-171. (Pubitemid 36966748)
14. Parker S, Touchette E, Oberle C, et al. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res. 2008;77(1):39-49.
15. Trost LC, Trippin TK, Anderson MT, Painter WP; Chimerix Inc Compromised renal function does not affect the pharmacokinetics of CMX001 in patients with severe double-stranded DNA virus infections. http://www.chimerix-inc.com/images/ uploads/2010%20ICAAC%20Poster.pdf. Accessed September 13, 2010.